Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (201 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-10-04. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cordpainconcomitant diseasecompletespinal
  Phrases that lowered it: patients whoinhibitorspatients withwith severeindividuals
• Sponsor's past termination rate: 13.0% (raises risk) · Sponsor's track record
• Design: crossover (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 13.3% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 63.2% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Blinding: quadruple (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports before start: 105137 (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 15 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pharmacological Agents for Chronic Spinal Cord Injury (SCI) NCT05708274 · started 2023 · scored riskier than 84% of active trials completed
• Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury NCT01484184 · started 2013 · scored riskier than 56% of active trials completed
• Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI NCT05589402 · started 2019 · scored riskier than 11% of active trials completed
• Mexiletine in Sporadic Amyotrophic Lateral Sclerosis NCT02781454 · started 2016 · scored riskier than 53% of active trials completed
• Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI NCT02458469 · started 2015 · scored riskier than 5% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.